CautionSeroxat
Paroxetine
SSRI with anticholinergic action
Avoid in pregnancy where alternatives exist (T1 cardiac risk).
Oral
First-line for
- OCD, PTSD — when other SSRIs failed and pregnancy is not planned
Mechanism
SERT inhibition + weak muscarinic antagonism → sedating profile, more discontinuation syndrome than other SSRIs.
"Paroxetine = Preventable T1 cardiac risk"
- Absolute cardiac malformation risk +0.5–1% (T1)
- Withdraw slowly — worst SSRI for discontinuation
- Switch preconception to sertraline
Dosing
- Depression
- 20 mg OD; max 50 mg
- OCD
- 40 mg OD; max 60 mg
Contraindications
- AbsoluteConcurrent MAOI
- CautionPlanned or confirmed T1 pregnancy
Side effects
- Anticholinergic (dry mouth, constipation)
- Weight gain
- Sexual dysfunction
- Marked discontinuation syndrome
Fetal & maternal notes
- • T1 exposure: OR 1.5–2 for cardiac defects (VSD/ASD)
- • Neonatal adaptation and PPHN like other SSRIs
Key interactions
Tamoxifen
AvoidPotent CYP2D6 inhibition ↓ endoxifen — AVOID
MAOIs, linezolid, tramadol
AvoidSerotonin syndrome
Clinical pearls
- 💡 If a woman becomes pregnant on paroxetine, do not stop abruptly — plan careful switch or continue if benefits > risks
- 💡 Fetal echocardiogram at 20 weeks if T1 exposure
Content last reviewed: REPLACE_ME (e.g. 2026-07)
Spotted something out of date? See our disclaimer or use Report an Error above.